NexGel (NXGLW) — Supplier relationships and what they mean for investors

NexGel manufactures high‑water‑content, electron‑beam crosslinked hydrogels and monetizes by selling finished hydrogel products to medical and device customers and by supplying formulated gels to partners who integrate them into regulated diagnostic and monitoring systems. The company runs a compact manufacturing and sourcing footprint: raw materials are purchased from a short list of chemical distributors and polymer producers, contract manufacturing and packaging are used for scale, and strategic revenue is generated through partner supply agreements such as the one with iRhythm. For actionable supplier intelligence and counterparty risk profiles, see https://nullexposure.com/.

Why supplier mapping matters for a small medical‑materials manufacturer

NexGel’s business model converts commodity polymers and formulation know‑how into differentiated medical adhesive and gel components sold into device channels. That model creates four investor‑relevant supplier dynamics: concentration of input sources, dependence on contract carriers and co‑manufacturers, partner-driven demand, and supply resilience provided by large chemical suppliers. Each dynamic influences margin stability, working capital, and execution risk when scaling clinical and commercial programs.

If you are evaluating counterparty exposure or vendor concentration for NXGLW, detailed relationship intelligence is available at https://nullexposure.com/.

Relationship-by-relationship: the essentials investors need

Below I summarize every disclosed supplier or partner relationship found in the public filings and calls, with a concise source note.

• Berry Global, Inc. — NexGel lists Berry Global as one of its principal suppliers for raw materials used in hydrogel production, indicating reliance on large packaging and polymer supply chains. According to NXGLW’s FY2024 Form 10‑K, Berry Global is named among principal raw‑material suppliers.
• DeWolf Chemical, Inc. — DeWolf Chemical is also identified as a principal supplier for raw materials, reflecting NexGel’s procurement from specialty chemical distributors. This is disclosed in the FY2024 Form 10‑K.
• Univar, Inc. — Univar is the third company NexGel cites as a principal supplier of raw materials, suggesting procurement through national chemical distributors that can provide scale and multiple polymer chemistries. The FY2024 Form 10‑K lists Univar alongside the other principal suppliers.
• United Parcel Service, Inc. (UPS) — NexGel ships finished gels to customers via contract carrier, explicitly naming UPS as an example of its logistics partners, which matters for fulfillment reliability and lead‑time risk. This logistics detail is contained in the FY2024 Form 10‑K.
• Innovative Optics — Management disclosed that an IRB study under FDA guidelines was funded by partner Innovative Optics, with results pending publication; this indicates a partner‑funded clinical or data generation relationship that supports product validation. The 2025 Q3 earnings call referenced this partner‑funded study.
• iRhythm (IRTC) — NexGel signed an agreement to supply hydrogels for iRhythm’s Zio ECG heart monitoring system, making iRhythm both a strategic customer and a partner for device integration; management discussed the May agreement during the 2025 Q3 earnings call.

Each of the above relationships is sourced from NXGLW’s public filings and recent quarterly comments; the FY2024 Form 10‑K supplies the supplier list and logistics description, while the 2025 Q3 earnings call provides partner and customer updates.

Company‑level supplier signals and constraints that matter

Company disclosures and extracted constraints give clean signals about NexGel’s operating posture:

• Large suppliers underpin supply adequacy. Management states that, “due to the size and scale of production of our suppliers, there should be an adequate supply of components and raw materials from our other suppliers,” a company‑level signal that supplier scale reduces single‑source risk.
• Use of manufacturers and service providers. Evidence in filings cites contract manufacturing and packaging arrangements (for example, transactions with CG Laboratories are referenced in support of contract manufacturing and packaging spend), and names leading polymer manufacturers such as Dow Chemical and BASF as sources of primary polymers used in hydrogel manufacture. These excerpts signal NexGel’s operating model relies on third‑party manufacturing and major polymer suppliers rather than in‑house polymer production.
• Contracting posture is partner‑oriented. The mix of named national distributors (Berry, DeWolf, Univar), a logistics carrier (UPS), contract manufacturers/packagers, and partner‑funded clinical activity describes a company that outsources non‑core production and relies on partners for clinical and commercial acceleration.

These constraints should be read as company‑level characteristics rather than as attributions to any single supplier unless the filings name them explicitly.

What this means for concentration, criticality and maturity

• Concentration: The raw‑material roster is short — three principal suppliers are named — which concentrates procurement risk but is partially offset by the suppliers’ scale. Concentration increases execution risk if a supplier faces disruption, but large distributors typically provide alternate sourcing and logistics coverage.
• Criticality: Polymers and formulation components are mission‑critical inputs; disruption would affect revenue conversion directly because finished gels require specific chemistries and packaging. The presence of contract manufacturers and large polymer suppliers indicates the company’s dependency on external specialist capabilities.
• Maturity: The supplier mix and partner profile indicate a company that is operationally mature in procurement (national distributors, contract packagers) but still commercially nascent — revenue TTM is approximately $11.7M with EBITDA negative roughly $2.53M and diluted EPS of -1.39 — so scale‑up risk is material while supplier relationships are relative strengths.

For investor due diligence on counterparty exposure, explore full relationship documents at https://nullexposure.com/.

Investment implications — risk and upside in plain terms

• Upside: The iRhythm supply agreement is a commercial catalyst: supplying a recognized cardiac monitoring platform presents a path to recurring, higher‑volume revenue if integration and reimbursement dynamics align. Management’s partner‑funded study (Innovative Optics) also supports clinical evidence generation that can open additional device pathways.
• Operational risk: A short supplier list increases procurement concentration risk; while suppliers are large, single‑source formulations or custom polymer grades can be sticky. Reliance on contract carriers and contract manufacturing introduces logistics and quality control dependencies that investors must monitor.
• Financial posture: NexGel’s current scale shows positive gross margin ($4.76M gross profit on ~$11.7M revenue) but operating losses persist (EBITDA negative $2.53M), meaning supplier terms, working capital management, and partner orders will materially affect near‑term cash flow and the company’s ability to scale.

Bottom line and next steps for analysts

NexGel operates with a deliberate outsourcing model: large distributors and polymer manufacturers supply raw materials, contract manufacturing and carriers handle production and fulfillment, and strategic partners supply clinical and commercial channels. That configuration reduces certain capital burdens but concentrates execution risk in supplier and logistics relationships. Investors should track the ramp of the iRhythm program, monitor any single‑source polymer dependencies, and validate contract manufacturing quality controls against scaled demand.

For a deeper vendor map, counterparty scoring, and to integrate this intelligence into procurement or investment models, visit https://nullexposure.com/. If you want tailored supplier risk analytics or to license the underlying relationship extractions for portfolio monitoring, start at https://nullexposure.com/ and request a demo.